ARTICLE | Clinical News
CHS-1701: Phase I data
October 12, 2015 7:00 AM UTC
Top-line data from a double-blind, crossover, U.S. Phase I trial in 116 healthy volunteers showed that a single subcutaneous injection of 6 mg CHS-1701 met the primary endpoint of biosimilarity to Ne...